Clinical Data, Inc. Expands FAMILION[R] Long QT Syndrome Test by Doubling the Number of Genes.

NEWTON, Mass. -- PGxHealth, a division of Clinical Data, Inc. (NASDAQ: CLDA), a biotechnology company developing targeted therapeutics and genetic and pharmacogenomic tests to detect diseases and predict drug safety, tolerability and efficacy, announced today at the Heart Rhythm Society meeting that it will double the number of genes in its FAMILION Long QT Syndrome (LQTS) Test. By detecting genetic mutations in individuals and their families, the FAMILION LQTS Test can help guide treatment to prevent possible sudden cardiac death. This newly enhanced LQTS Test follows the 3-gene expansion of the FAMILION Hypertrophic Cardiomyopathy (HCM) Test released earlier this year and demonstrates the Company's leadership in genetic testing for inherited cardiac disorders.

"The addition of these five LQTS genes demonstrates our commitment to expand the scope of our tests as the clinical utility of new information is endorsed by the medical community," said Drew Fromkin, President and CEO of Clinical Data. "We are also pleased that the investments we have made in our laboratory operations, physician and patient support services and payor reimbursement function will enable us to offer this enhanced LQTS Test without increasing our price."

Also at the Heart Rhythm meeting, PGxHealth scientists, together with academic collaborators, are presenting three scientific abstracts relating to inherited cardiac conditions. Presentations include:

* Spectrum and Prevalence of Mutations for the First 2500 Consecutive Unrelated LQTS Patients Referred for FAMILION([R]) Long QT Syndrome Genetic Testing. Abstract # PO03-4

* A Worldwide Compendium of Putative Brugada Syndrome Associated Mutations in the SCN5A-Encoded Cardiac Sodium Channel. Abstract # PO06-6

* Case-Control Genetic Comparison of the Cardiac Ryanodine Receptor in Catecholaminergic Polymorphic Ventricular Tachycardia. Abstract # PO02-160

"PGxHealth welcomes the opportunity to join academicians and healthcare providers from around the world again this year at the Heart Rhythm Society meeting, as we continue to disseminate vital information that will advance the understanding of heart disease and further inform treatment decisions," said Carol R. Reed, MD, Executive Vice President and Chief Medical Officer of Clinical Data.

In related news, PGxHealth has filed a patent application with the Unites States Patent and Trademark Office pertaining to 336 new mutations in the Long QT genes. "This patent filing builds upon our existing intellectual property in LQTS testing and is consistent with our commitment to bring new and enhanced tests to physicians and their patients," added Fromkin.

For More Information on the FAMILION family of tests, please contact PGxHealth Customer Service at 877-2-PGxHealth (877-274-9432) or visit www.pgxhealth.com.

About PGxHealth

PGxHealth, a division of Clinical Data, Inc., is utilizing its biomarker expertise and intellectual property to develop and commercialize targeted therapeutics as well as genetic and pharmacogenomic tests that detect serious diseases and help to predict drug safety and efficacy. By using innovative technologies and working with some of the world's most prestigious genomics thought leaders and institutions, PGxHealth is focused on improving clinical outcomes and reducing treatment costs in disease states and therapeutic classes with expensive, inefficient or suboptimal treatment options. Among its tests are the FAMILION([R]) and the PGxPredict([R])brands. Please visit the website at www.pgxhealth.com.

About Clinical Data, Inc.

Clinical Data is a global biotechnology company unlocking the potential of genomic discovery, From Targeted Science to Better Healthcare([R]). The Company is utilizing its biomarker expertise and intellectual property to develop and commercialize targeted therapeutics, as well as genetic and pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy, thereby improving health while reducing costs. Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, healthcare professionals and payors worldwide. To learn more, please visit the Company's website at www.clda.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether our PGxPredict([R]) tests, including but not limited to FAMILION([R]), will gain wide acceptance in the market; the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2008, Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2008, and Current Reports on Form 8-K filed from time to time by the Company.